Meeting
2023 ASCO Annual Meeting
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
Authors
Jayesh Desai
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Jayesh Desai , Jose Luis Iglesias , Lina T Jablonskis , Shaun McColl , Simon C Barry , Maria Pia Morelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3632)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3632
Abstract #
TPS3632
Poster Bd #
328a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2019 Gastrointestinal Cancers Symposium
A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini
Poster
2016 Gastrointestinal Cancers Symposium
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
First Author: Li-Tzong Chen